Kristen Sgambat1, Matthew B Matheson2, Stephen R Hooper3, Bradley Warady4, Susan Furth5, Asha Moudgil6. 1. Department of Nephrology, Children's National Health System, 111 Michigan Ave NW, Washington DC, 20010, USA. ksgambat@childrensnational.org. 2. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 3. University of North Carolina School of Medicine, Chapel Hill, NC, USA. 4. Pediatric Nephrology, Children's Mercy Kansas City, Kansas City, MO, USA. 5. Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. 6. Department of Nephrology, Children's National Health System, 111 Michigan Ave NW, Washington DC, 20010, USA.
Abstract
BACKGROUND: Frailty is a condition of decreased physiologic reserve and increased vulnerability to stressors. Frailty in combination with inflammation has been associated with increased mortality risk in adults with advanced chronic kidney disease (CKD). This study aimed to investigate prevalence and outcomes associated with a frailty-inflammation phenotype, or "fragility," in children with CKD. METHODS: We analyzed 557 children (age 6-19 years, eGFR 30-90 ml/min/1.73 m2) from the Chronic Kidney Disease in Children (CKiD) study. Based on adult models, the CKiD fragility model included four indicators: (1) suboptimal growth/weight gain (BMI < 5th percentile-for-height-age, deceleration ≥ 10 BMI-for-height-age percentiles/1 year, height-for-age percentile < 3rd or deceleration ≥ 10 height percentiles/1 year); (2) low muscle mass (mid-upper-arm circumference < 5th percentile or deceleration ≥ 10 percentiles/1 year); (3) fatigue (parent/child report); (4) inflammation (CRP > 3 mg/l). Logistic regression was used to evaluate association of fragility indicators with three adverse outcomes: frequent infection (> 1 per year/3 years), hospitalization (any), and rapid CKD progression (decline in eGFR > 30% or initiation of renal replacement therapy within 3 years). RESULTS: Prevalence of fragility indicators 1 year after study entry were 39% (suboptimal growth/weight gain), 62% (low muscle mass), 29% (fatigue), and 18% (inflammation). Prevalence of adverse outcomes during the subsequent 3 years were 13% (frequent infection), 22% (hospitalization), and 17% (rapid CKD progression). Children with ≥ 3 fragility indicators had 3.16-fold odds of frequent infection and 2.81-fold odds of hospitalization, but did not have rapid CKD progression. CONCLUSIONS: A fragility phenotype, characterized by the presence of ≥ 3 indicators, is associated with adverse outcomes, including infection and hospitalization in children with CKD.
BACKGROUND: Frailty is a condition of decreased physiologic reserve and increased vulnerability to stressors. Frailty in combination with inflammation has been associated with increased mortality risk in adults with advanced chronic kidney disease (CKD). This study aimed to investigate prevalence and outcomes associated with a frailty-inflammation phenotype, or "fragility," in children with CKD. METHODS: We analyzed 557 children (age 6-19 years, eGFR 30-90 ml/min/1.73 m2) from the Chronic Kidney Disease in Children (CKiD) study. Based on adult models, the CKiD fragility model included four indicators: (1) suboptimal growth/weight gain (BMI < 5th percentile-for-height-age, deceleration ≥ 10 BMI-for-height-age percentiles/1 year, height-for-age percentile < 3rd or deceleration ≥ 10 height percentiles/1 year); (2) low muscle mass (mid-upper-arm circumference < 5th percentile or deceleration ≥ 10 percentiles/1 year); (3) fatigue (parent/child report); (4) inflammation (CRP > 3 mg/l). Logistic regression was used to evaluate association of fragility indicators with three adverse outcomes: frequent infection (> 1 per year/3 years), hospitalization (any), and rapid CKD progression (decline in eGFR > 30% or initiation of renal replacement therapy within 3 years). RESULTS: Prevalence of fragility indicators 1 year after study entry were 39% (suboptimal growth/weight gain), 62% (low muscle mass), 29% (fatigue), and 18% (inflammation). Prevalence of adverse outcomes during the subsequent 3 years were 13% (frequent infection), 22% (hospitalization), and 17% (rapid CKD progression). Children with ≥ 3 fragility indicators had 3.16-fold odds of frequent infection and 2.81-fold odds of hospitalization, but did not have rapid CKD progression. CONCLUSIONS: A fragility phenotype, characterized by the presence of ≥ 3 indicators, is associated with adverse outcomes, including infection and hospitalization in children with CKD.
Authors: Kenneth Rockwood; Xiaowei Song; Chris MacKnight; Howard Bergman; David B Hogan; Ian McDowell; Arnold Mitnitski Journal: CMAJ Date: 2005-08-30 Impact factor: 8.262
Authors: Stanisław Niemczyk; Hanna Sikorska; Andrzej Wiecek; Ewa Zukowska-Szczechowska; Klaudia Załecka; Joanna Gorczyńska; Małgorzata Kubik; Beata Czerwieńska; Katarzyna Gosek; Johannes D Veldhuis; David A Wagner; Pierrette Gaudreau; Tiina Hakonen; Sam Wai Kit Kay; Taneli Jouhikainen; Franz Schaefer Journal: Kidney Int Date: 2009-12-16 Impact factor: 10.612
Authors: Susan L Furth; Stephen R Cole; Marva Moxey-Mims; Frederick Kaskel; Robert Mak; George Schwartz; Craig Wong; Alvaro Muñoz; Bradley A Warady Journal: Clin J Am Soc Nephrol Date: 2006-07-19 Impact factor: 8.237
Authors: Mara A McAdams-DeMarco; Andrew Law; Megan L Salter; Brian Boyarsky; Luis Gimenez; Bernard G Jaar; Jeremy D Walston; Dorry L Segev Journal: J Am Geriatr Soc Date: 2013-05-27 Impact factor: 7.538
Authors: Julien Hogan; Michael F Schneider; Rima Pai; Michelle R Denburg; Amy Kogon; Ellen R Brooks; Frederick J Kaskel; Kimberly J Reidy; Jeffrey M Saland; Bradley A Warady; Susan L Furth; Rachel E Patzer; Larry A Greenbaum Journal: Pediatr Nephrol Date: 2020-01-13 Impact factor: 3.714
Authors: Emma Jacobine Verwaaijen; Annelienke van Hulst; Marta Fiocco; Annelies Hartman; Martha Grootenhuis; Saskia Pluijm; Rob Pieters; Erica van den Akker; Marry M van den Heuvel-Eibrink Journal: JMIR Res Protoc Date: 2022-04-11
Authors: Adrian Post; Joëlle C Schutten; Daan Kremer; Yvonne van der Veen; Dion Groothof; Camilo G Sotomayor; Christa A Koops; Pim de Blaauw; Ido P Kema; Ralf Westerhuis; Theo Wallimann; M Rebecca Heiner-Fokkema; Stephan J L Bakker; Casper F M Franssen Journal: J Transl Med Date: 2021-03-20 Impact factor: 5.531